

RECEIVED

JUN 01 2001
Sheet 1 of 1

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO GNN-5315DV1		TECH CENTER 1600/2900 09/627,898	
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)							
APPLICANT Man Sung Co et al.						GROUP 1648	
FILING DATE July 27, 2000							

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B1 6,084,067	07/00	Freeman et al.	530	350	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	B2 WO 95/34320	12/95	PCT			YES NO
	B3 WO 96/14865	05/96	PCT			

OTHERS (Including Author, Title, Date, Pertinent Pages, Etc.)

B4	Alegre, M-L. et al., Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors," <i>Digestive Diseases and Sciences</i> , 40(1):58-64 (1995)
B5	Bree, A.G. et al., "Humanized anti-B7-1 and anti-B7-2 antibodies prevent antigen specific induction of immunity in nonhuman primates immunized with tetanus toxoid and mumps virus vaccine," <i>Blood</i> , 94(10) Suppl. 1 part 1, p. 439a (1999)
B6	Hathcock, K.S. et al., "Role of the CD28-B7 costimulatory pathways in T cell-dependent B cell responses," <i>Advances in Immunology</i> , 62:131-166 (1996)
B7	Lenschow, D.J. et al., "Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse," <i>J. Exp. Med.</i> , 181:1145-1155 (1995)
B8	Lenschow, D.J. et al., "Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies," <i>Transplantation</i> , 60:1171-1178 (1995)
B9	Wettendorff, M. et al., "Generation of humanized Fab fragments of B7-24 mAb, an antibody with potential use in the prevention of graft rejection and development of graft-versus-host disease," <i>Med. Fac. Landbouwkundige en toegepaste biologische</i> , 60:2057-2063 (1995)
Examiner _____ Date Considered _____	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

JUN 01 2001
Sheet 1 of 1

OF PUBLICATIONS
(Use several sheets)
MAY 29 2001
PATENT & TRADEMARK OFFICE

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MC	B1 6,084,067	07/00	Freeman et al.	530	350	

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>ml</i>	B2	WO 95/34320	12/95	PCT				
<i>ml</i>	B3	WO 96/14865	05/96	PCT				

	B4	Alegre, M-L. et al., "Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors," <i>Digestive Diseases and Sciences</i> , 40(1):58-64 (1995)
	B5	Bree, A.G. et al., "Humanized anti-B7-1 and anti-B7-2 antibodies prevent antigen specific induction of immunity in nonhuman primates immunized with tetanus toxoid and mumps virus vaccine," <i>Blood</i> , 94(10) Suppl. 1 part 1, p. 439a (1999)
	B6	Hathcock, K.S. et al., "Role of the CD28-B7 costimulatory pathways in T cell-dependent B cell responses," <i>Advances in Immunology</i> , 62:131-166 (1996)
	B7	Lenschow, D.J. et al., "Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse," <i>J. Exp. Med.</i> , 181:1145-1155 (1995)
	B8	Lenschow, D.J. et al., "Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies," <i>Transplantation</i> , 60:1171-1178 (1995)
	B9	Wettendorff, M. et al., "Generation of humanized Fab fragments of B7-24 mAb, an antibody with potential use in the prevention of graft rejection and development of graft-versus-host disease," <i>Med. Fac. Landbouwkundige en toegepaste biologische</i> , 60:2057-2063 (1995)
Examiner		Date Considered
*EXAMINER:		Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SIGNED
copy

Philip Gambel 6/14/04
FIRST CONSIDERED 2/25/02